ReviewMolecular medicine reports2026
T‑cadherin and its impact on human diseases (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adipokines as Regulators of Nitric Oxide Synthase Isoforms Across Organs: Emerging Implications for Gastrointestinal Motility.International journal of molecular sciences · 2026Review
- CaAntibodies (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Truncated‑cadherin (T‑cadherin) is a distinct glycosylphosphatidylinositol‑anchored atypical cadherin that differs from classical cadherins since it does not have transmembrane and intracellular domains. It primarily functions as a dual receptor, serving as a physiological receptor for low‑density lipoprotein (LDL) and a specific receptor for high‑molecular‑weight (HMW) adiponectin. Upon binding to LDL, T‑cadherin activates calcium signaling, thereby promoting cell proliferation and migration and contributing to the development of atherosclerotic plaques. Conversely, its interaction with HMW adiponectin mediates cardiovascular protective effects through various mechanisms, such as increased exosome secretion, reduced intracellular ceramide accumulation, improved insulin sensitivity and anti‑inflammatory actions. T‑cadherin is predominantly expressed in cardiovascular tissues, such as endothelial cells, smooth muscle cells, pericytes and cardiomyocytes. Genetic polymorphisms in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.